C4X Discovery Holdings PLC Total Voting Rights (5038V)

TIDMC4XD

RNS Number : 5038V

C4X Discovery Holdings PLC

13 December 2021

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Total Voting Rights

13 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that pursuant to its block admission facility, details of which were announced on 1 July 2021, it has recently issued 1,100,000 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") in satisfaction of the exercise of warrants. The new Ordinary Shares rank pari passu with the Company's existing shares.

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, as of 13 December 2021, the Company has 228,912,697 Ordinary Shares in issue. There are no shares held in treasury. The total number of voting rights in the Company is therefore 228,912,697.

The above figure of 228,912,697 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

- Ends -

Contacts

 
 C4X Discovery Holdings 
 Mo Noonan, Communications                    [phone] 
 
 Panmure Gordon (UK) Limited (NOMAD and 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate 
  Finance)                                    [phone] 
 Rupert Dearden (Corporate Broking) 
 
 C4X Discovery Media - Consilium Strategic 
  Communications 
 Mary-Jane Elliott, Chris Gardner, Matthew 
  Neal                                        [phone] 
 

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRDKNBKFBDDCBD

(END) Dow Jones Newswires

December 13, 2021 13:11 ET (18:11 GMT)